Association Between the Polymorphism in miR-605 and Cancer Susceptibility: a PRISMA-Compliant Meta-Analysis.

MicroRNAs (miRNAs) play important roles in cancer development. miR-605 was reported in several studies and showed potential as a prognostic biomarker. However, the association between miR-605 and the risk of cancer remained controversial in previous studies. Therefore, this meta-analysis was carried out to elaborate the association between polymorphism in miR-605 and cancer susceptibility. PubMed, Embase, Ovid Medline, and CNKI were searched for eligible studies through up to April 2018. The pooled odds ratios (ORs) with 95% confidence intervals (CIs) were derived from a random effects model. Statistical analysis was performed using STATA10.0 software or Review Manager 5.3 software. A total of 8 eligible studies consisting of 2,462 cases and 3,716 controls were included in this meta-analysis. The ORs and 95% CIs in the 4 genetic models were (GA+GG vs. AA: OR = 0.97, 95% CI: 0.97, 1.19; GG vs. GA+AA: OR = 1.09, 95% CI: 0.81, 1.47; GG vs. AA: OR = 1.19, 95% CI: 0.77, 1.82; GA vs. AA: OR = 0.94, 95% CI: 0.77, 1.15). When stratified by cancer type and race, the results showed that polymorphism in miR-605 (rs2043556) is a protective factor for cancer in Asian population. But rs2043556 could increase the susceptibility of head and neck squamous cell carcinoma (NSCC) in the dominant genotype model. The results of subgroup analysis of race (Asian: GA+GG vs. AA: OR = 0.86, 95% CI: 0.75, 1.00; GA vs. AA: OR = 0.82, 95% CI: 0.72, 0.92) and of cancer type (NSCC: GA+GG vs. AA: OR = 1.36, 95% CI: 1.14, 1.61). The current meta-analysis demonstrated that the rs2043556 may decrease susceptibility in Asian populations, especially allelic-G may be a protective factor for cancer in carriers.